Form 13-F position report

PHARMACYTE BIOTECH INC COM NEW

Reported by MORGAN STANLEY

PMCB CUSIP 71715X203 Manager CIK 0000895421

Reported 3 shares, down 18 (85.7%) from the prior quarter.

Reported value -86.7%; share count -85.7% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q3 2023
Shares 3 Quarter-end amount reported
Reported value $8 Fair value at quarter end
Consecutive quarters held 9 Through Q3 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 170000
2022-03-31 142000
2022-06-30 6000
2022-09-30 0
2022-12-31 161
2023-03-31 90
2023-06-30 60
2023-09-30 8
2023-12-31 9
2024-03-31 9
2024-06-30 7
2024-09-30 5
2024-12-31 4
2025-03-31 2
2025-06-30 0
2025-09-30 10
2025-12-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for PHARMACYTE BIOTECH INC COM NEW held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q4 2025 Reduced 0 -9 (-100.0%) 0 $0 2026-02-13
Q3 2025 New 9 +9 (0.0%) < 0.01% $10 2025-11-14
Q2 2025 Reduced 0 -1 (-100.0%) 0 $0 2025-08-15
Q1 2025 Reduced 1 -1 (-50.0%) < 0.01% $2 2025-05-15
Q4 2024 Unchanged 2 0 (0.0%) < 0.01% $4 2025-02-14
Q3 2024 Reduced 2 -1 (-33.3%) < 0.01% $5 2024-11-14
Q2 2024 Unchanged 3 0 (0.0%) < 0.01% $7 2024-08-14
Q1 2024 Reduced 3 -1 (-25.0%) < 0.01% $9 2024-05-15
Q4 2023 Added 4 +1 (33.3%) < 0.01% $9 2024-02-13
Q3 2023 Reduced 3 -18 (-85.7%) < 0.01% $8 2023-11-15
Q2 2023 Reduced 21 -10 (-32.3%) < 0.01% $60 2023-08-14
Q1 2023 Reduced 31 -24 (-43.6%) < 0.01% $90 2023-05-15
Q4 2022 Added 55 +24 (77.4%) < 0.01% $161 2023-02-14
Q3 2022 Reduced 31 -2,495 (-98.8%) 0 $0 2022-11-14
Q2 2022 Reduced 2,526 -59,343 (-95.9%) < 0.01% $6,000 2022-08-15
Q1 2022 Reduced 61,869 -6,264 (-9.2%) < 0.01% $142,000 2022-05-13
Q4 2021 Added 68,133 +67,102 (6508.4%) < 0.01% $170,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

34 managers reported PHARMACYTE BIOTECH INC COM NEW for Q3 2023.

Managers reporting PHARMACYTE BIOTECH INC COM NEW in Q3 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Ayrton Capital LLC Reduced 92,087 -184,905 1.31% $193,383,000 8 qtrs
K2 PRINCIPAL FUND L P Added 258,481 +104,249 0.11% $542,810 6 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 219,110 +36 < 0.01% $460,158 9 qtrs
VANGUARD GROUP INC Reduced 168,921 -14,661 < 0.01% $354,734 8 qtrs
SABBY MANAGEMENT LLC New 97,124 +97,124 0.15% $203,960 1 qtr
EQUITEC PROPRIETARY MARKETS LLC Added 82,727 +21,312 0.04% $173,727 8 qtrs
BlackRock Inc Reduced 41,713 -1,605 < 0.01% $87,597 6 qtrs
CITADEL ADVISORS LLC Reduced 35,384 -29,524 < 0.01% $74,306 6 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 32,900 +7,026 < 0.01% $69,000 2 qtrs
DIMENSIONAL FUND ADVISORS LP Added 29,307 +4 < 0.01% $61,545 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2023
Filed
November 15, 2023
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
1
Shared
0
None
2

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.